Daxor (DXR) Stock Price, News & Analysis

Company Overview

Daxor Corporation is a medical device company that develops and commercializes diagnostic technologies for measuring blood volume. Its primary product is the BVA-100 Blood Volume Analyzer, which uses an automated tracer-dilution technique to measure a patient’s total blood volume, red blood cell volume and plasma volume.

The BVA-100 is designed to support clinical assessment and management in areas such as heart failure, critical care, blood disorders and other conditions in which a patient’s fluid or blood-volume status is important. By providing quantitative blood-volume information, the system is intended to help healthcare professionals evaluate fluid status and guide treatment decisions.

Founded in 1972, Daxor is headquartered in New York and focuses on advancing blood-volume measurement technology for use by hospitals, medical centers and research institutions. The company is led by Chief Executive Officer Michael Feldschuh. Its operations and commercial reach are centered on the development and distribution of its medical diagnostic products.

Key Stats

• Today's Range: $10.44 to $11.59
• 50-Day Range: $9.67 to $11.72
• 52-Week Range: $8.56 to $14.76
• Volume: 11,712 shs
• Average Volume: 44,129 shs
• Market Capitalization: $66.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Daxor Stock Analysis - MarketRank™

Daxor scored higher than 33% of companies evaluated by MarketBeat, and ranked 743rd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Daxor has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Daxor has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of Daxor has been sold short.

Short Interest Ratio / Days to Cover

Daxor has a short interest ratio ("days to cover") of 0.04, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Daxor has recently increased by 293.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Daxor does not currently pay a dividend.

Dividend Growth

Daxor does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Daxor has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Daxor this week, compared to 1 article on an average week.

Search Interest

1 people have searched for DXR on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Daxor insiders have not sold or bought any company stock.

Percentage Held by Insiders

51.50% of the stock of Daxor is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

1.34% of the stock of Daxor is held by institutions.

Company Calendar

• Today: 9/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:DXR
• Previous Symbol: NYSEAMERICAN:DXR
• CIK: 27367
• Web: www.daxor.com
• Phone: 212-244-0555
• Fax: 212-244-0806
• Employees: 37
• Year Founded: 1970

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 5,840,000
• Free Float: 2,831,000
• Market Cap: $66.28 million
• Optionable: Not Optionable
• Beta: 0.26